Inovio Pharmaceuticals (INO) Cash from Investing Activities (2010 - 2026)

Inovio Pharmaceuticals has reported Cash from Investing Activities for 17 years, with the latest figure at $2.6 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 5193.15% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.7 million (down 71.47% YoY) and the FY2025 annual result came in at $14.0 million, down 86.51% from the prior year.
• Cash from Investing Activities advanced to $2.6 million in Q1 2026 per INO's latest filing, from -$58189.0 in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $54.0 million in Q4 2022 and troughed at -$10.3 million in Q2 2022.
• A 5-year average of $18.7 million and a median of $14.1 million in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities plunged 120.48% in 2022, then surged 5193.15% in 2026.
• Over 5 years, Cash from Investing Activities stood at $54.0 million in 2022, then sank by 63.07% to $19.9 million in 2023, then soared by 73.71% to $34.6 million in 2024, then plunged by 100.17% to -$58189.0 in 2025, then surged by 4629.82% to $2.6 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $2.6 million, -$58189.0, and $8.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.